Predictive value of soluble ST-2 in left ventricular function and structural changes in breast cancer patients receiving doxorubicin chemotherapy_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

DUAN Qi ¹ ,  YANG Yingtao ¹ , YANG Qing ² , LIU Xiaozhe ¹

1. Department of Breast Surgery, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, P. R. China;
2. Department of Ultrasound Diagnosis, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, P. R. China;

Corresponding?author：

YANG Yingtao, Email: yangyingtao001@126.com

Keywords：

breast cancer; anthracycline; soluble carcinogenesis inhibitor 2; cardiac function

DOI：

10.7507/1007-9424.201906089

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To evaluate whether soluble carcinogenesis inhibitor 2 (ST-2) level can be used as indicators for predicting left ventricular dysfunction by detecting sST-2 and other cardiac function indexes in patients with breast cancer who receiving doxorubicin chemotherapy.Methods A retrospective study of 90 breast cancer patients who received doxorubicin (pyrubicin) chemotherapy in the Department of Breast Surgery, The Fifth Affiliated Hospital of Zhengzhou University from September 2016 to June 2018 was performed. Peripheral venous blood samples were collected before chemotherapy and one year after receiving doxorubicin chemotherapy, to detect sST-2 level and cardiac function indexes, and echocardiography was performed at the same time.Results Compared with pre-chemotherapy, sST-2, left ventricular end-systolic volume (LVESV), left ventricular end diastolic volume (LVEDV), left ventricular systolic diameter (LVESD), left ventricular diastolic internal diameter (LVEDD), and E/e' value increased at one year after chemotherapy, while left ventricular eject fraction (LVEF) decreased, the difference was statistically significant (P<0.05). There was a negative correlation between the level of sST-2 and LVEF (r=–0.618, P<0.05). The receiver operating characteristic curve (ROC) showed that the 11.9 ng/mL of sST-2 concentration was the best threshold to predict left ventricular dysfunction, and the sensitivity and specificity were 90.6% and 69.2%, respectively, the area under the ROC curve was 0.836 (P<0.05).Conclusion sST-2 has a certain diagnostic value for predicting left ventricular function and structural changes in breast cancer patients who receiving doxorubicin chemotherapy.

Citation： DUAN Qi, YANG Yingtao, YANG Qing, LIU Xiaozhe. Predictive value of soluble ST-2 in left ventricular function and structural changes in breast cancer patients receiving doxorubicin chemotherapy. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2020, 27(2): 147-151. doi: 10.7507/1007-9424.201906089 Copy

1.	Stewart B, Wild C. World cancer report 2014. Lyon: WHO Press, 2014: 362-373.
2.	World Health Organization. Globocan 2012 v1.0. 2017-03-04. http://globocan.iarc.fr.
3.	Oeffinger KC, Fontham ET, Etzioni R, et al. Breast cancer screening for women at average risk: 2015 guideline update from the American Cancer Society. JAMA, 2015, 314(15): 1599-1614.
4.	Apuri S. Neoadjuvant and adjuvant therapies for breast cancer. South Med J, 2017, 110(10): 638-642.
5.	司徒紅林, 張蓉, 陳前軍. 蒽環類化療藥物在治療乳腺癌中的應用. 廣東醫學, 2006, 27(10): 1579-1581.
6.	Rygiel K. Benefits of antihypertensive medications for anthracycline- and trastuzumab-induced cardiotoxicity in patients with breast cancer: insights from recent clinical trials. Indian J Pharmacol, 2016, 48(5): 490-497.
7.	Cardinale D, Colombo A, Bacchiani G, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation, 2015, 131(22): 1981-1988.
8.	Drafts BC, Twomley KM, D’Agostino R Jr, et al. Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease. JACC Cardiovasc Imaging, 2013, 6(8): 877-885.
9.	Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med, 1979, 91(5): 710-717.
10.	Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol, 2002, 20(5): 1215-1221.
11.	Bayes-Genis A, Januzzi JL, Gaggin HK, et al. ST2 pathogenetic profile in ambulatory heart failure patients. J Card Fail, 2015, 21(4): 355-361.
12.	Zheng L, Tan W, Zhang J, et al. Combining trastuzumab and cetuximab combats trastuzumab-resistant gastric cancer by effective inhibition of EGFR/ErbB2 heterodimerization and signaling. Cancer Immunol Immunother, 2014, 63(6): 581-586.
13.	Florescu M, Cinteza M, Vinereanu D. Chemotherapy-induced cardiotoxicity. Maedica (Buchar), 2013, 8(1): 59-67.
14.	胡夕春, 張劍, 陳德滇, 等. 中國蒽環類藥物治療乳腺癌專家共識. 中國腫瘤臨床, 2018, 45(3): 120-125.
15.	Lukianova NY, Andriiv AV, Chekhun VF. Correlation of iodine symporter expression in highly and low malignant cell lines of human breast cancer differed in their sensitivity to doxorubicin. Exp Oncol, 2016, 38(3): 169-171.
16.	McGowan JV, Chung R, Maulik A, et al. Anthracycline chemotherapy and cardiotoxicity. Cardiovasc Drugs Ther, 2017, 31(1): 63-75.
17.	Sawyer DB. Anthracyclines and heart failure. N Engl J Med, 2013, 368(12): 1154-1156.
18.	Bansal N, Amdani S, Lipshultz ER, et al. Chemotherapy-induced cardiotoxicity in children. Expert Opin Drug Metab Toxicol, 2017, 13(8): 817-832.
19.	Mueller T, Dieplinger B, Gegenhuber A, et al. Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure. Clin Chem, 2008, 54(4): 752-756.
20.	孫愛梅, 劉婷, 陳還珍. 可溶性 ST2 對冠心病的危險分層價值及其與心功能的關系. 中國心血管雜志, 2017, 22(1): 19-23.
21.	Ky B, French B, McCloskey K, et al. High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circ Heart Fail, 2011, 4(2): 180-187.
22.	Broch K, Ueland T, Nymo SH, et al. Soluble ST2 is associated with adverse outcome in patients with heart failure of ischaemic aetiology. Eur J Heart Fail, 2012, 14(3): 268-277.
23.	牛琳, 趙敏, 周芳, 等. 重復測量分析左心房最小容積與最大容積在評價蒽環類藥物所致心臟毒性中的應用價值. 溫州醫科大學學報, 2018, 48(11): 807-812.
24.	Huang DH, Sun H, Shi JP. Diagnostic value of soluble suppression of tumorigenicity-2 for heart failure. Chin Med J (Engl), 2016, 129(5): 570-577.
25.	Januzzi JL Jr, Peacock WF, Maisel AS, et al. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J Am Coll Cardiol, 2007, 50(7): 607-613.
26.	Aimo A, Vergaro G, Passino C, et al. Prognostic value of soluble suppression of tumorigenicity-2 in chronic heart failure: a meta-analysis. JACC Heart Fail, 2017, 5(4): 280-286.
27.	韓榮麗, 張焱, 薛紅梅, 等. 老年慢性心力衰竭患者可溶性致癌抑制因子 2 的水平及臨床意義. 中國老年學雜志, 2017, 37(1): 97-99.
28.	Huang G, Zhai J, Huang X, et al. Predictive value of soluble ST-2 for changes of cardiac function and structure in breast cancer patients receiving chemotherapy. Medicine (Baltimore), 2018, 97(38): e12447.

1. Stewart B, Wild C. World cancer report 2014. Lyon: WHO Press, 2014: 362-373.
2. World Health Organization. Globocan 2012 v1.0. 2017-03-04. http://globocan.iarc.fr.
3. Oeffinger KC, Fontham ET, Etzioni R, et al. Breast cancer screening for women at average risk: 2015 guideline update from the American Cancer Society. JAMA, 2015, 314(15): 1599-1614.
4. Apuri S. Neoadjuvant and adjuvant therapies for breast cancer. South Med J, 2017, 110(10): 638-642.
5. 司徒紅林, 張蓉, 陳前軍. 蒽環類化療藥物在治療乳腺癌中的應用. 廣東醫學, 2006, 27(10): 1579-1581.
6. Rygiel K. Benefits of antihypertensive medications for anthracycline- and trastuzumab-induced cardiotoxicity in patients with breast cancer: insights from recent clinical trials. Indian J Pharmacol, 2016, 48(5): 490-497.
7. Cardinale D, Colombo A, Bacchiani G, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation, 2015, 131(22): 1981-1988.
8. Drafts BC, Twomley KM, D’Agostino R Jr, et al. Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease. JACC Cardiovasc Imaging, 2013, 6(8): 877-885.
9. Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med, 1979, 91(5): 710-717.
10. Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol, 2002, 20(5): 1215-1221.
11. Bayes-Genis A, Januzzi JL, Gaggin HK, et al. ST2 pathogenetic profile in ambulatory heart failure patients. J Card Fail, 2015, 21(4): 355-361.
12. Zheng L, Tan W, Zhang J, et al. Combining trastuzumab and cetuximab combats trastuzumab-resistant gastric cancer by effective inhibition of EGFR/ErbB2 heterodimerization and signaling. Cancer Immunol Immunother, 2014, 63(6): 581-586.
13. Florescu M, Cinteza M, Vinereanu D. Chemotherapy-induced cardiotoxicity. Maedica (Buchar), 2013, 8(1): 59-67.
14. 胡夕春, 張劍, 陳德滇, 等. 中國蒽環類藥物治療乳腺癌專家共識. 中國腫瘤臨床, 2018, 45(3): 120-125.
15. Lukianova NY, Andriiv AV, Chekhun VF. Correlation of iodine symporter expression in highly and low malignant cell lines of human breast cancer differed in their sensitivity to doxorubicin. Exp Oncol, 2016, 38(3): 169-171.
16. McGowan JV, Chung R, Maulik A, et al. Anthracycline chemotherapy and cardiotoxicity. Cardiovasc Drugs Ther, 2017, 31(1): 63-75.
17. Sawyer DB. Anthracyclines and heart failure. N Engl J Med, 2013, 368(12): 1154-1156.
18. Bansal N, Amdani S, Lipshultz ER, et al. Chemotherapy-induced cardiotoxicity in children. Expert Opin Drug Metab Toxicol, 2017, 13(8): 817-832.
19. Mueller T, Dieplinger B, Gegenhuber A, et al. Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure. Clin Chem, 2008, 54(4): 752-756.
20. 孫愛梅, 劉婷, 陳還珍. 可溶性 ST2 對冠心病的危險分層價值及其與心功能的關系. 中國心血管雜志, 2017, 22(1): 19-23.
21. Ky B, French B, McCloskey K, et al. High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circ Heart Fail, 2011, 4(2): 180-187.
22. Broch K, Ueland T, Nymo SH, et al. Soluble ST2 is associated with adverse outcome in patients with heart failure of ischaemic aetiology. Eur J Heart Fail, 2012, 14(3): 268-277.
23. 牛琳, 趙敏, 周芳, 等. 重復測量分析左心房最小容積與最大容積在評價蒽環類藥物所致心臟毒性中的應用價值. 溫州醫科大學學報, 2018, 48(11): 807-812.
24. Huang DH, Sun H, Shi JP. Diagnostic value of soluble suppression of tumorigenicity-2 for heart failure. Chin Med J (Engl), 2016, 129(5): 570-577.
25. Januzzi JL Jr, Peacock WF, Maisel AS, et al. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J Am Coll Cardiol, 2007, 50(7): 607-613.
26. Aimo A, Vergaro G, Passino C, et al. Prognostic value of soluble suppression of tumorigenicity-2 in chronic heart failure: a meta-analysis. JACC Heart Fail, 2017, 5(4): 280-286.
27. 韓榮麗, 張焱, 薛紅梅, 等. 老年慢性心力衰竭患者可溶性致癌抑制因子 2 的水平及臨床意義. 中國老年學雜志, 2017, 37(1): 97-99.
28. Huang G, Zhai J, Huang X, et al. Predictive value of soluble ST-2 for changes of cardiac function and structure in breast cancer patients receiving chemotherapy. Medicine (Baltimore), 2018, 97(38): e12447.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Predictive value of soluble ST-2 in left ventricular function and structural changes in breast cancer patients receiving doxorubicin chemotherapy

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content